Management of Patients Presenting with Acute Psychotic Episodes of Schizophrenia

被引:31
|
作者
Thomas, Pierre [1 ]
Alptekin, Koeksal [2 ]
Gheorghe, Mihai [3 ]
Mauri, Mauro [4 ]
Manuel Olivares, Jose [5 ]
Riedel, Michael [6 ]
机构
[1] Univ Lille, Sch Med, Dept Psychiat, Lille, France
[2] Dokuz Eylul Univ, Sch Med, Dept Psychiat, Izmir, Turkey
[3] Clin Cent Mil Hosp, Dept Psychiat, Bucharest, Romania
[4] Univ Milan, Dept Clin Psychiat, Milan, Italy
[5] Vigo Univ Hosp, Dept Psychiat, Pontevedra, Spain
[6] Univ Munich, Dept Psychiat & Psychotherapy, Munich, Germany
关键词
CONVENTIONAL ANTIPSYCHOTIC-DRUGS; D2-DOPAMINE RECEPTOR OCCUPANCY; NEUROLEPTIC MALIGNANT SYNDROME; COMORBID SUBSTANCE-ABUSE; DOUBLE-BLIND TRIAL; SEXUAL DYSFUNCTION; LONG-TERM; ATYPICAL ANTIPSYCHOTICS; 1ST-EPISODE PSYCHOSIS; DEPRESSIVE SYMPTOMS;
D O I
10.2165/00023210-200923030-00002
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
The initial management of patients with schizophrenia presenting to psychiatric emergency departments with an acute psychotic episode requires rapid decisions to be made by physicians concerning the treatment of individuals who are likely to be relatively uncooperative, agitated and lacking insight. The treatment decision must be adapted to the individual characteristics and needs of each patient. This article reviews the issues from the perspective of the initial management of acute psychosis as it is currently practised in Europe, and discusses the pragmatic implications for initial treatment decisions and the elaboration of a long-term treatment plan. Initially, administration of antipsychotics to control psychotic symptoms and benzodiazepines to control agitation represents the cornerstone of treatment. Oral medication is preferable to injectable forms wherever possible, and atypical antipsychotics are to be preferred over conventional agents because of their lower risk of extrapyramidal adverse effects, which are a major determinant of poor adherence to treatment. Whatever antipsychotic is chosen by the physician during the initial period, it is likely that it will need to be continued for many years, and it is thus important to take into account the long-term safety profile of the drug chosen, particularly in relation to extrapyramidal adverse effects, metabolic complications and quality of life. Building a therapeutic alliance with the patient and his/her family or carers is an important element that should be included in the initial management of psychosis. The long-term goal should be to minimize the risk of psychotic relapse through adequate treatment adherence.
引用
收藏
页码:193 / 212
页数:20
相关论文
共 50 条